# Program 30: Neuro-Oncology

> **NIH CA P30** · DANA-FARBER CANCER INST · 2026 · $63,200

## Abstract

Neuro-Oncology Program 
Project Summary / Abstract 
Neuro-Oncology has been a CCSG disease-based Program since 2005, with the mission to improve standards 
of care for cancers of the nervous system. The Program features a broad portfolio of research initiatives in the 
general clinical disciplines and in therapeutically relevant scientific areas. Over the past two funding cycles, we 
prioritized work on astrocytomas – the most lethal brain tumor of adults and the most common brain tumor of 
childhood. Going forward, we will extend our work on astrocytomas and broaden our clinical and translational 
profile with an initiative on hereditary and sporadic neoplasms driven by loss-of-function mutations in the 
Neurofibromin 2 (NF2) gene. We will also explore new therapeutic opportunities from the emerging field of 
cancer neuroscience. In accord with the Director’s Strategic Vision, contemporary tools of medicinal chemistry 
will be brought to bear upon “undruggable” oncogenic drivers and tumor-specific, epigenetic, and metabolic 
vulnerabilities will be exploited as therapeutic targets. The immunosuppressive glioma microenvironment will 
be targeted with personalized, synthetic peptide neoantigen vaccines and with bi-valent CART cells that 
release anti-EGFR antibodies within the local environment of tumor cells. 
Skill sets of the leadership team (T. BatchelorBWH, D. Haas-KoganDFCI/BCH/BWH, S. PlotkinMGH, and M. SuvaMGH) 
align with Program strategies and research priorities. The Program’s 98 members (87 primary and 11 
secondary) draw from all seven DF/HCC institutions and 15 academic departments. Peer-reviewed funding in 
2019 was $13.1 M (direct costs, representing an increase from $12.2M reported in 2014), of which $8.9 M was 
from NCI. Components of the support package include a renewed SPORE grant on glioma a K12 training grant 
on Neuro Oncology. From 2016 to 2019, Program primary members generated 955 peer-reviewed 
publications. Inter-programmatic collaboratio

## Key facts

- **NIH application ID:** 11322569
- **Project number:** 5P30CA006516-61
- **Recipient organization:** DANA-FARBER CANCER INST
- **Principal Investigator:** Tracy T Batchelor
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** CA
- **Fiscal year:** 2026
- **Award amount:** $63,200
- **Award type:** 5
- **Project period:** 1997-03-10T00:00:00 → 2026-11-30T00:00:00

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11322569

## Citation

> US National Institutes of Health, RePORTER application 11322569, Program 30: Neuro-Oncology (5P30CA006516-61). Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/grant/nih/11322569. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*